{
  "id": "clinical#risk_safety_1af6cc06",
  "content": "mine), serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine,\nsertraline), and monoamine oxidase inhibitors (e.g., phenelzine,\nselegiline, pargyline). The incidence of this syndrome depends on\nthe dosage and half-life of the medication being taken, as well as the\nrate at which the medication is tapered. Short-acting medications\nthat are stopped abruptly rather than tapered gradually may pose\nthe greatest risk. The short-acting selective serotonin reuptake in-\nhibitor (SSRI) paroxetine is the agent most commonly associated with\ndiscontinuation symptoms, but such symptoms occur for all types of\nantidepressants.\nUnlike withdrawal syndromes associated with opioids, alcohol,\nand other substances of abuse, antidepressant discontinuation syn-\n352 Medication-Induced Movement Disorders\ndrome has no pathognomonic symptoms. Instead, the symptoms tend\nto be vague and variable and typically begin 2–4 days after the last dose\nof the antidepressant. For SSRIs (e.g., paroxetine), symptoms such as\ndizziness, ringing in the ears, “electric shocks in the head,” an inability to\nsleep, and acute anxiety are described. The antidepressant use prior to\ndiscontinuation must not have incurred hypomania or euphoria (i.e.,\nthere should be confidence that the discontinuation syndrome is not the\nresult of fluctuations in mood stability associated with the previous\ntreatment). The antidepressant discontinuation syndrome is based",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "sleep",
      "risk_safety",
      "screening_cues",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Risk Safety mine), serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine,\nsertraline), and monoamine oxidase inhibitors (e.g., phenelzine,\nselegiline, pargyline). The incidence of this syndrome depends on\nthe dosage and half-life of the medication being taken, as well as the\nrate at which the medication is tapered. Short-acting medications\nthat are stopped abruptly rather than tapered gradually may pose\nthe greatest risk. The short-acting selective serotonin reuptake in-\nhibitor (SSRI) paroxetine is the agent most commonly associated with\ndiscontinuation symptoms, but such symptoms occur for all types of\nantidepressants.\nUnlike withdrawal syndromes associated with opioids, alcohol,\nand other substances of abuse, antidepressant discontinuation syn-\n352 Medication-Induced Movement Disorders\ndrome has no pathognomonic symptoms. Instead, the symptoms tend\nto be vague and variable and typically begin 2–4 days after the last dose\nof the antidepressant. For SSRIs (e.g., paroxetine), symptoms such as\ndizziness, ringing in the ears, “electric shocks in the head,” an inability to\nsleep, and acute anxiety are described. The antidepressant use prior to\ndiscontinuation must not have incurred hypomania or euphoria (i.e.,\nthere should be confidence that the discontinuation syndrome is not the\nresult of fluctuations in mood stability associated with the previous\ntreatment). The antidepressant discontinuation syndrome is based Mine), serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine,\nsertraline), and monoamine oxidase inhibitors (e.g., phenelzine,\nselegiline, pargyline). the incidence of this syndrome depends on\nthe dosage and half-l..."
}